The Era of Big Pharma Fraud Cases Is Ending, Former US Attorney Loucks Says, But It May Go Out With A Bang
This article was originally published in RPM Report
The pace of whistleblower cases against Big Pharma companies is winding down, former prosecutor says. It may not seem that way, with a full pipeline of pending investigations likely to dominate the headlines for months or even years to come, but Big Pharma is finally coming into compliance. This era may end with a bang: Loucks believes there is significant pressure to exclude a corporation for fraud.
You may also be interested in...
Pfizer’s Lipitor goes generic—albeit with some decidedly unusual wrinkles. The biggest generic launch in history is a good moment to take stock of the transition away from the blockbuster model. The reaction to the milestone suggests that the industry’s critics may be having a harder time letting go of the old model than industry is.
Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.
Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.